Literature DB >> 3281909

Heterogeneity among strains and a high rate of variation within strains of a major surface antigen of Mycoplasma pulmonis.

H L Watson1, L S McDaniel, D K Blalock, M T Fallon, G H Cassell.   

Abstract

Monoclonal and monospecific antibodies were used to characterize a major Mycoplasma pulmonis surface antigen complex, V-1. Heterogeneity of V-1 was detected among strains and a high frequency of variation was detected within subclones of single strains. Analysis of 18 different strains showed that no two displayed identical electrophoretic immunoblot patterns for V-1. Analysis of 50 filter clones from an individual strain (not previously filter cloned) revealed at least 10 different V-1 patterns. The two most frequently occurring patterns were expressed by 36% and 24%, respectively, of the total population. Serial subcloning (four separate series) of several of these original clones showed that the average rate of V-1 variation was 2 x 10(-3) per cell per generation. Immunoblots with different anti-V-1 monoclonal antibodies demonstrated that there were both structurally and antigenically different forms of this antigen. Also, two-dimensional polyacrylamide gel analyses showed that different forms of V-1 could vary in charge. This potential for variability in a major surface antigen of mycoplasmas could have important implications as to how the organism interacts with its host.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3281909      PMCID: PMC259832          DOI: 10.1128/iai.56.5.1358-1363.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.

Authors:  J F Kearney; A Radbruch; B Liesegang; K Rajewsky
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

2.  High resolution two-dimensional electrophoresis of proteins.

Authors:  P H O'Farrell
Journal:  J Biol Chem       Date:  1975-05-25       Impact factor: 5.157

3.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  A rapid sensitive silver stain for polypeptides in polyacrylamide gels.

Authors:  C R Merril; M L Dunau; D Goldman
Journal:  Anal Biochem       Date:  1981-01-01       Impact factor: 3.365

6.  Experimental Mycoplasma pulmonis infection in pathogen-free mice. Models for studying mycoplasmosis of the respiratory tract.

Authors:  J R Lindsey; H Cassell
Journal:  Am J Pathol       Date:  1973-07       Impact factor: 4.307

7.  Lymphocyte activation by various Mycoplasma strains and species.

Authors:  Y Naot; J G Tully; H Ginsburg
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

8.  Mycoplasmal adherence with particular reference to the pathogenicity of Mycoplasma pulmonis.

Authors:  D Taylor-Robinson; P M Furr; H A Davies; R J Manchee; C Mouches; J M Bove
Journal:  Isr J Med Sci       Date:  1981-07

9.  Protective effect of vaccines on Mycoplasma pulmonis-induced respiratory disease of mice.

Authors:  G Taylor; C J Howard; R N Gourlay
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

10.  Endotoxin protein: a B-cell mitogen and polyclonal activator of C3H/HeJ lymphocytes.

Authors:  B M Sultzer; G W Goodman
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

View more
  31 in total

1.  The vsp locus of Mycoplasma bovis: gene organization and structural features.

Authors:  I Lysnyansky; K Sachse; R Rosenbusch; S Levisohn; D Yogev
Journal:  J Bacteriol       Date:  1999-09       Impact factor: 3.490

2.  Gene rearrangements in the vsa locus of Mycoplasma pulmonis.

Authors:  X Shen; J Gumulak; H Yu; C T French; N Zou; K Dybvig
Journal:  J Bacteriol       Date:  2000-05       Impact factor: 3.490

3.  Resistance to antimicrobial peptides and stress response in Mycoplasma pulmonis.

Authors:  Lina Fassi Fehri; Pascal Sirand-Pugnet; Géraldine Gourgues; Gwenaël Jan; Henri Wróblewski; Alain Blanchard
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Serotype diversity and antigen variation among invasive isolates of Ureaplasma urealyticum from neonates.

Authors:  X Zheng; H L Watson; K B Waites; G H Cassell
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

5.  High-frequency variation in Mycoplasma pulmonis colony size.

Authors:  K Dybvig; J W Simecka; H L Watson; G H Cassell
Journal:  J Bacteriol       Date:  1989-09       Impact factor: 3.490

6.  Mycoplasma synoviae has two distinct phase-variable major membrane antigens, one of which is a putative hemagglutinin.

Authors:  A H Noormohammadi; P F Markham; K G Whithear; I D Walker; V A Gurevich; D H Ley; G F Browning
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

7.  Genotypic and phenotypic analysis of Mycoplasma fermentans strains isolated from different host tissues.

Authors:  L Campo; P Larocque; T La Malfa; W D Blackburn; H L Watson
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

8.  Monoclonal antibodies that inhibit mitogenic activity of Mycoplasma pulmonis.

Authors:  Z Lapidot; R Siman-Tov; Y Naot
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

9.  Cytopathic effects of Mycoplasma pulmonis in vivo and in vitro.

Authors:  C T Stadtländer; H L Watson; J W Simecka; G H Cassell
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

10.  The Vsa proteins modulate susceptibility of Mycoplasma pulmonis to complement killing, hemadsorption, and adherence to polystyrene.

Authors:  Warren L Simmons; Kevin Dybvig
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.